Aintree University Hospital NHS Foundation Trust NCRI - - PowerPoint PPT Presentation

NCRI Hepatobiliary trials portfolio

Hassan Z Malik MD, FRCS

Aintree University Hospital

NHS Foundation Trust

Consultant Hepatobiliary Surgeon

Number of NIHR studies available for recruiting patients each year

100 200 300 400 500 600 700 800 Total number of studies open to recruitment Non-commercial studies open to recruitment Commercial studies open to recruitment

Number of NIHR studies available for recruiting patients

713 cancer studies recruited patients since 1/4/15: 132 studies in rare cancers with ASR <3 225 studies in cancers with ASR <6 74 [or more] studies of cancer surgery 64 [or more] studies of radiotherapy 46 paediatric oncology studies 164 commercially sponsored studies

Remit of the HB sub-group

• Hepatocellular carcinoma
• Cholangiocarcinoma
• Gallbladder carcinoma
• Colorectal liver metastases*
• CUP

Our Aims: To improve outcomes for patients with HB cancer through progressive clinical trials and cutting edge translational research

The clinical problem of liver malignancy in the UK

• There has been a 70%

increase in HB malignancy which is now ranked 18th in the UK

• Colorectal cancer remains

major problem with up to 50% patients developing liver dominant metastases

Cancer registration statistics 2014 data – first release

Achievements of the group

• Studies with published results:

ABC-02, New EPOC, Photostent 2, ABC-03, and ABC-O4

• Closed studies and awaiting results:

BilCap and TACE2

• Studies in set-up:

ACTTICA 1 and HTA - 13/153/04

• On going translational research in all closed

and currently recruiting studies. Links to 100,000 genome project

The current portfolio map

How to get in involved

• Information on the website: http://csg.ncri.org.uk/wp-

content/uploads/2014/11NCRI-Upper-GI-CSG- AnnualReport-2014-15.pdf

• Contact the chair of the group:

hassan.malik@aintree.nhs.uk

• Come to the annual trials meeting

BASO/NCRI meeting Liverpool 2016